PD-1 Archives -

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

https://pharmaphorum.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug/

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in

Henlius claims win for PD-1 drug in small cell lung cancer

https://pharmaphorum.com/news/henlius-claims-win-for-pd-1-drug-in-small-cell-lung-cancer/

GlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with

Immuno-oncology latecomer GSK shows off PD-1 drug data

https://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/

BMS and Nektar’s combination latest in frenzied immunotherapy field

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.

Promise for combination approach to cancer

https://pharmaphorum.com/views-and-analysis/promise-combination-approach-cancer/

PD-1